Setmelanotide
Brand names: Imcivree · Active ingredient: Setmelanotide
In short: IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged : 4 years and older with acquired hypothalamic obesity (HO) 2 years and older with syndromic or monogenic obesity due to: o Bardet-Biedl syndrome (BBS) o Pro-opiomelanocor
What is Setmelanotide used for?
IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged :
4 years and older with acquired hypothalamic obesity (HO)
2 years and older with syndromic or monogenic obesity due to:
o Bardet-Biedl syndrome (BBS)
o Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).
IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:
• Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign.
• Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
Setmelanotide dosage
Acquired HO
Select patients for treatment with IMCIVREE who have acquired HO .
BBS
Select patients for treatment with IMCIVREE who have a clinical diagnosis of BBS
.Consider genetic confirmation in pediatric patients aged <6 years.
POMC, PCSK1, or LEPR Deficiency
Select patients for treatment with IMCIVREE who have genetically determined or suspected deficiency of POMC, PCSK1, or LEPR
.
Treat patients with variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) in the clinical context of the patient
.
An FDA-approved test for the detection of variants in the POMC, PCSK1, or LEPR genes is not available.
Monitor patients for gastrointestinal (GI) adverse reactions during dosage initiation and titration
.
If the starting dosage is:
Not tolerated, discontinue the product.
Tolerated for 2 weeks, increase the dosage as presented in Table 1 or Table 2.
Adults and Pediatric Patients Aged 6 Years and Older
The recommended starting dosage is 0.5 mg (0.05 mL) injected subcutaneously once daily for 2 weeks.
Pediatric Patients Aged 4 to Less Than 6 Years
The recommended starting dosage is 0.5 mg (0.05 mL) injected subcutaneously once daily for 2 weeks.
Adults and Pediatric Patients Aged 12 Years and Older
The recommended starting dosage is 2 mg (0.2 mL) injected subcutaneously once daily for 2 weeks in adults and pediatric patients aged 12 years and older.
Monitor patients for GI adverse reactions during dosage initiation and titration
.
If the starting dosage is:
Not tolerated, reduce the dosage to 1 mg (0.1 mL) once daily. If the 1 mg once daily dosage is tolerated for at least 1 week, increase the dosage to 2 mg (0.2 mL) once daily.
Tolerated for 2 weeks, increase the dosage to 3 mg (0.3 mL) once daily. If the 3 mg once daily dosage is not tolerated, decrease the dosage to 2 mg (0.2 mL) once daily.
The recommended maintenance dosage is 3 mg (0.3 mL) injected subcutaneously once daily.
Pediatric Patients Aged 6 to Less Than 12 Years
The recommended starting dosage is 1 mg (0.1 mL) injected subcutaneously once daily for 2 weeks in pediatric patients aged 6 to less than 12 years.
Monitor patients for GI adverse reactions during dosage initiation and titration
.
If the starting dosage is:
Not tolerated, reduce the dosage to 0.5 mg (0.05 mL) once daily. If the 0.5 mg once daily dosage is tolerated for at least 1 week, increase the dosage to 1 mg (0.1 mL) once daily.
Tolerated for 2 weeks, increase the dosage to 2 mg (0.2 mL) once daily. If the 2 mg daily dosage is:
Not tolerated, reduce the dosage to 1 mg (0.1 mL) once daily.
Tolerated, increase the dosage to 3 mg (0.3 mL) once daily.
The recommended maintenance dosage is 3 mg (0.3 mL) injected subcutaneously once daily. …
How to take Setmelanotide — instructions & advice from the label
Advise the patient and caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Disturbance in Sexual Arousal
Inform patients and caregivers that sexual adverse reactions, including spontaneous erection, may occur in patients treated with IMCIVREE. Advise patients to seek emergency medical treatment if an erection lasts longer than 4 hours
.
Depression and Suicidal Ideation
Inform patients and caregivers that IMCIVREE may cause depression or suicidal ideation. Advise patients and caregivers to report any new or worsening symptoms of depression, suicidal thoughts or behaviors, or unusual changes in mood or behavior
.
Hypersensitivity Reactions
Inform patients and caregivers that serious hypersensitivity reactions have been reported with use of IMCIVREE. Advise patients and caregivers on the symptoms of hypersensitivity reactions and instruct them to stop taking IMCIVREE and seek medical advice promptly if such symptoms occur
. …
Warnings & precautions
Do not take this medicine if: IMCIVREE is contraindicated in patients with a prior serious hypersensitivity reaction to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions have included anaphylaxis
.
Sexual adverse reactions may occur in patients treated with IMCIVREE. Spontaneous penile erections and increased frequency of penile erections in males occurred in clinical trials with IMCIVREE
.
Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.
Some drugs that target the central nervous system, such as IMCIVREE, may cause depression or suicidal ideation . Patients with a history of depression or suicidal ideation may be at increased risk for recurrent episodes while taking IMCIVREE.
Monitor patients for new onset or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors or if clinically significant or persistent depression symptoms occur.
Serious hypersensitivity reactions, including anaphylaxis, have been reported with IMCIVREE. These reactions generally occurred within minutes to hours after injecting IMCIVREE
.
If hypersensitivity reactions occur, advise patients to promptly seek medical attention and discontinue use of IMCIVREE. IMCIVREE is contraindicated in patients with a prior serious hypersensitivity reaction to setmelanotide or any of the excipients in IMCIVREE.
Generalized or focal increases in skin pigmentation occurred in the majority of IMCIVREE-treated patients in clinical trials . This effect is reversible upon discontinuation of the drug.
IMCIVREE may also cause the development of new melanocytic nevi or darkening of pre-existing nevi due to its pharmacologic effect. …
Setmelanotide side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Disturbance in Sexual Arousal
Depression and Suicidal Ideation
Hypersensitivity Reactions
Skin Hyperpigmentation, Darkening of Pre-Existing Nevi, and Development of New Melanocytic Nevi
Acute Adrenal Insufficiency in Patients with Acquired HO
Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Acquired HO (Adults and Pediatric Patients Aged 4 Years and Older)
The safety of IMCIVREE was evaluated in a randomized, double-blind, placebo-controlled clinical trial which included a dose titration period of 4 to 8 weeks and a 52-week treatment period, in 142 patients aged 4 years and older with acquired HO (Trial 1)
. The trial duration was 56 to 60 weeks.
Table 5 summarizes the adverse reactions that occurred in 5% or more of the IMCIVREE-treated patients and more frequently than placebo-treated patients in Trial 1.
Other Adverse Reactions in Patients Aged 4 Years and Older with Acquired HO
Disturbance in Sexual Arousal
Spontaneous penile erections and increased frequency of penile erections were reported in 7% of IMCIVREE-treated patients and 4% of placebo-treated patients. …
About this medicine
IMCIVREE contains setmelanotide acetate, a melanocortin 4 (MC4) receptor agonist. Setmelanotide is an 8 amino acid cyclic peptide analog of endogenous melanocortin peptide α‑MSH (alpha-melanocyte stimulating hormone).
The chemical name for setmelanotide acetate is acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidinyl-D-phenylalanyl-L-arginyl-L-tryptophanyl-L-cysteinamide cyclic (2→8)-disulfide acetate. Its molecular formula is C
49H
68N
18O
9S
2(anhydrous, free-base), and molecular mass is 1117.3 Daltons (anhydrous, free-base).
The chemical structure of setmelanotide acetate is:
IMCIVREE (setmelanotide) injection is a sterile clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 70c3ccf7-4df0-4c75-ba07-fede9970c8d9. Read the full official label on DailyMed.
Related medicines
Tirzepatide Methylphenidate Lisdexamfetamine Amphetamine Orlistat Serdexmethylphenidate and Dexmethylphenidate Benzphetamine Phendimetrazine